MAM
CNCE

Meeder Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Meeder Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,895
Closed -$16K – 2601
2020
Q1 		$16K Buy
1,895
+1,034
+120% +$10.2K ﹤0.01% 1340
2019
Q4 		$8K Sell
861
-451
-34% -$3.2K ﹤0.01% 1657
2019
Q3 		$8K Buy
1,312
+1,013
+339% +$10.7K ﹤0.01% 1620
2019
Q2 		$4K Buy
+299
New +$3.21K ﹤0.01% 1759
2019
Q1 		– Sell
-137
Closed -$2K – 1919
2018
Q4 		$2K Buy
137
+109
+389% +$1.5K ﹤0.01% 1594
2018
Q3 		$0 Sell
28
-6,277
-100% -$98.8K ﹤0.01% 1733
2018
Q2 		$106K Buy
6,305
+5,496
+679% +$107K 0.01% 619
2018
Q1 		$19K Buy
809
+593
+275% +$13.2K ﹤0.01% 906
2017
Q4 		$5K Sell
216
-12
-5% -$242 ﹤0.01% 1333
2017
Q3 		$3K Sell
228
-129
-36% -$1.87K ﹤0.01% 1405
2017
Q2 		$5K Buy
357
+60
+20% +$884 ﹤0.01% 1218
2017
Q1 		$5K Sell
297
-1,205
-80% -$14.5K ﹤0.01% 1111
2016
Q4 		$15K Buy
+1,502
New +$13.7K ﹤0.01% 695

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Meeder Asset Management's CNCE Position: Q2 2020 in Review

Meeder Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2020, closing a stake of 1,895 shares — an estimated $16K sold.

Meeder Asset Management first reported a position in CNCE in Q4 2016 and held it in 13 quarters. The position peaked at $106K in Q2 2018. 91 funds tracked by Wall St. Rank hold CNCE as of Q2 2020.

  • Meeder Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,895 Concert Pharmaceuticals, Inc. shares in Q2 2020, an estimated $16K.
  • Meeder Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2016 and held it in 13 quarters.
  • Meeder Asset Management's Concert Pharmaceuticals, Inc. position peaked at $106K in Q2 2018.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.